Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma

NCT07488533 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Non-Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Serplulimab in combination with Fruquintinib

Sponsor

Sun Yat-sen University